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Abstract: The prediction of birth weight may be improved by the measurement of hormones or growth factors in 
the mother. We measured body weight (BW) and plasma levels of placental GH (PGH), IGF-I, IGF-binding 
protein-1 (IGFBP-1), and leptin at the time of the glucose challenge test (GCT) in 289 women, who were 
pregnant with a single fetus, between 24 and 29 wk gestational age (GA). Delivery occurred 12 ± 2 (mean ± SD) 
wk later. 
First, we examined which variables regulate these hormonal factors. Multiple regression showed that PGH 
concentrations were determined by GA at sampling and were negatively related to BW. IGF-I levels were mainly 
determined by PGH, and also by insulin, BW, and (negatively) age. IGFBP-1 concentrations were negatively 
determined by BW, insulin, and IGF-I. BW was also a powerful determinant of leptin levels, with insulin as a 
less robust determinant. 
Second, we examined the relation to glucose levels. PGH, IGF-I, and IGFBP-1 concentrations were not 
correlated with post-GCT glucose levels and were comparable in women with a normal or disturbed GCT 
(glucose ≥7.8 mmol/liter; n = 72). 
Finally, we examined the relation with birth weight and placental weight. Birth weight, corrected for GA and 
stratified into percentile groups, and the ponderal index at birth were strongly related to maternal BW, but not to 
maternal PGH, IGF-I, or IGFBP-1 levels. Neither was maternal leptin related to birth weight, but leptin 
concentrations were slightly higher in women who delivered obese babies. Placental weight was not related to 
any of the hormonal factors. 
This prospective study indicates that the variation in circulating PGH, IGF-I, IGFBP-1, and leptin between 24 
and 29 wk of pregnancy is strongly dependent on maternal BW, but is unrelated to glucose tolerance. In addition, 
the measurement of PGH, IGF-I, IGFBP-1, or leptin at the time of the GCT is not useful clinically to predict 
birth weight.  
Abbreviations: BMI, Body mass index; BW, body weight; CV, coefficients) of variation; GA, gestational age; GCT, glucose challenge test; 
GDM, gestational diabetes mellitus; IGFBP-1, IGF binding protein 1; IUGR, in utero growth retardation; LSD, least significant difference; 
P, percentile; PGH, placental GH; PI, ponderal index; rh, recombinant human. 
In utero growth retardation (IUGR) and overgrowth (macrosomia) are associated with increased perinatal 
complications, including fetal distress, neonatal hypoglycemia, and perinatal death. In addition, both IUGR and 
macrosomia have long-term effects on body size and composition and increase the risk of developing features of 
the metabolic syndrome (1). More specifically, thin and obese babies [i.e. babies with a low or high ponderal 
index (PI), respectively] appear to be the most at risk (1). The clinical and ultrasonic prediction of birth weight 
and PI may be improved by additional biochemical measurements. These potential biochemical markers include 
growth-related hormones and growth factors such as placental GH (PGH), IGF-I, IGF-binding protein-1 
(IGFBP-1), and leptin, which could be measured in amniotic fluid or, preferably, in maternal serum at some 
point during pregnancy. These growth-related factors do not cross the placental barrier, but may affect fetal 
growth through their effects on the placenta (2). 
PGH is secreted by the syncytiotrophoblast and is believed to be responsible for the gradual rise in serum IGF-I 
concentrations during the second half of pregnancy, because PGH and IGF-I levels are correlated (3, 4). 
Circulating IGFBP-1 increases from early pregnancy onward (5, 6) and is produced by both liver and decidua 
(7). There is also a surge in serum leptin during pregnancy, owing to the accumulation of adipose tissue and the 
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placental production of leptin (8, 9). 
Several studies have demonstrated lower circulating levels of PGH and IGF-I, but higher levels of IGFBP-1, 
during the third trimester of pregnancies complicated by IUGR, in particular pregnancies with a deficient 
uteroplacental supply line (4, 10-14). Maternal serum IGFBP-1 was also found to correlate negatively with birth 
weight in normal (15,16) and diabetic (17) pregnancies. In addition, maternal leptin levels were inversely 
correlated with birth weight in adolescent pregnancies (18) and in pregnancies complicated by gestational 
diabetes mellitus (GDM) (19). 
Methodological aspects limit the conclusions that can be drawn from these studies. In some studies, women were 
sampled throughout pregnancy (16). Other studies focused on pregnancies in which IUGR was already 
diagnosed (4, 11-14) and samples were taken shortly before delivery (4, 11-13); in these studies, lower PGH and 
IGF-I may reflect a lower placental mass. Some studies did not correct birth weight for gestational age (GA) 
(15,16). Finally, most studies did not correct for the effect of maternal body weight (BW), which has a powerful 
effect on maternal IGFBP-1 (16,20) and leptin levels (18) - and perhaps on PGH and IGF-I levels, and also on 
birth weight (21). 
We therefore decided to study PGH, IGF-I, IGFBP-1, and leptin levels at the time of the glucose challenge test 
(GCT), because the number of blood samples performed on a routine basis during pregnancy is limited. A GCT 
is generally done between 24 and 28 wk as a screening test for GDM (22). Maternal BW at this time was 
included as a measurement. 
The experimental setting offered the additional bonus to examine the relation of PGH and IGFBP-1 with glucose 
levels. Insulin resistance is well known to arise in the second half of pregnancy, accelerating the development of 
glucose intolerance (23). Although acromegaly and GH administration in nonpregnant individuals induce insulin 
resistance (24,25), the link between PGH and insulin resistance/glucose intolerance during pregnancy is 
unknown. Recently, PGH concentrations at 28 wk were found to be positively correlated with postprandial, but 
not fasting, glucose levels (14). On the other hand, the addition of glucose to villous tissue cultures resulted in a 
sharp reduction of PGH output in vitro (26). Increased IGFBP-1 levels during pregnancy may also promote 
glucose intolerance. Indeed, the acute infusion of IGFBP-1 blocked the hypoglycemic response to IGF-I and 
raised glucose levels in rats (27), and transgenic mice that overexpress the IGFBP-1 gene develop glucose 
intolerance (28). 
Materials and Methods 
Study population 
The study protocol was approved by the Ethical Committee of the Katholieke Universiteit Leuven Faculty of 
Medicine. The study population consisted of women who had a GCT, ordered by their obstetrics/ gynecology 
physician, in the antenatal clinic between May and September 2000. Fasting or nonfasting women received 100 
ml of a lemon-flavored 50% glucose solution (50 g of glucose) and received an extra 100 ml of water if they 
wanted it. GCTs were performed throughout the day, between 0900 and 1900 h. Patients were given a leaflet 
explaining the purpose of the study during the time they had to wait for the blood sampling. In the meantime, 
patients were requested not to eat, drink, smoke, or chew gum, and not to walk about. After 60 min, they were 
asked whether they consented to participate in the study, which consisted of donating an extra blood tube in 
addition to the tests ordered by the physician. This extra blood tube was kept at 4 C, centrifuged on a twice daily 
basis, aliquoted, and frozen at -80 C until assayed. Clinical data were retrieved from the computerized file notes 
after delivery; there was no interference with clinical management. 
Three hundred thirty-nine samples were obtained; 50 samples were discarded, either because they were taken 
from women carrying twins (n = 5) or because they were taken at 30-wk GA or later (n = 39) or before 24-wk 
GA (n = 6); however, we included the 47 samples taken at 29-wk GA in the study. The recorded BW was 
determined at the time of the GCT; the recorded height was determined at the first antenatal visit, and the body 
mass index (BMI) was calculated. None of the mothers had known glucose intolerance before the GCT. In 14 
patients (4.9%), glucose intolerance was clinically detected on the basis of the GCT result and a subsequent oral 
glucose tolerance test, and they were treated with a 1600-1800 kcal diabetes diet (n = 12) or with a diet 
combined with insulin (n = 2). Thirty-eight patients (13.7%) developed some form of hypertension during 
pregnancy, according to the classification of Davey and MacGillivray (29); 7 of them (2.5%) developed 
preeclampsia, 21 developed gestational hypertension, and 10 had chronic hypertension. Eleven patients dropped 
out from the antenatal clinic between the GCT and delivery, or they delivered elsewhere; thus, the delivery data 
Published in: Journal of Clinical Endocrinology and Metabolism (2002), vol.87, iss.6, pp.2875-2882 
Status: Postprint (Author’s version) 
pertain to 278 women/newborns. Birth weight was compared with recently updated reference charts, derived 
from more than 429,000 births in Flanders, Belgium, and was stratified into percentile groups according to GA 
(30). The PI at birth was calculated as: birth weight in grams X 100/(length in centimeters) (3). Newborns were 
stratified into three categories: thin (PI <2.32), normal (PI between 2.32 and 2.84), and obese (PI ≥2.85) (31). 
There were no major congenital abnormalities in the cohort, except for one newborn who had a pulmonary artery 
abnormality that did not require neonatal surgery. 
Assays 
All assays were done in a single run, and all measurements were done in duplicate. Plasma glucose was 
measured by the glucose-oxidase method with a YSI 2300 Stat Plus glucometer (YSI, Inc., Yellow Springs, 
OH); we did not use the glucose values, measured for clinical management. Insulin was measured by RIA, with 
recombinant human (rh) insulin as the standard, and a polyclonal rabbit antiserum (32); the detection limit of this 
assay is 15 pmol/liter, and the between-assay coefficient of variation (CV) is 3.2-5.9%. PGH was measured by a 
two-site immunoradiometric assay, using rhPGH as the standard and two monoclonal antibodies. The detection 
limit is about 10 pmol/liter; within- and between-assay CV are 3.0-5.5% and 5.0-7.9%, respectively (33-35). 
IGF-I was measured by RIA after acid ethanol extraction, using rhIGF-I as the standard and a polyclonal 
antiserum raised in guinea pigs. The detection limit is about 5 nmol/liter, and within- and between-assay CV are 
10.8 and 7.6%, respectively (35-37). IGFBP-1 was measured by RIA, using as standard IGFBP-1 purified from 
human amniotic fluid standardized to an enzyme-linked immunoassay from Medix Biochemica (Kauniainen, 
Finland) and an antiserum raised in rabbits, and was described in detail previously (37); the detection limit is 
about 10 pmol/liter, and within- and between-assay CV are 2.4-4.0% and 6.2-9.7%, respectively. Leptin was 
measured with a commercial RIA kit (Linco Research, Inc., St. Charles, MO); the detection limit is about 30 
pmol/liter, and within- and between-assay CV are 3.4-8.3% and 3.0-6.2%, respectively. 
Data analysis 
Using a software program (NCSS, Kaysville, UT), analyses included: t tests and χ2 tests, one-way ANOVA 
followed by Fisher's least significant difference (LSD) multiple comparison test, two-factor ANOVA, pair-wise 
Pearson correlation matrices, and multiple regression. Data are shown as means ± SD. 
Results 
General characteristics 
Maternal age varied between 15 and 44 yr (Table 1). Using age distribution data, we calculated that the study 
cohort was older compared with the entire parturient population of Flanders, Belgium, in 1999 (38) (χ2 test, P < 
0.0001). One hundred forty women (48%) were nulliparous, 99 (34%) were para 1, and 50 (17%) were 
multiparous. The large majority (n = 272, 94%) was of European (Caucasian) ancestry, whereas 17 were of non-
European or uncertain ancestry. Mean GA at delivery was 38.9 wk (SD, 1.6; range, 26-42 wk); delivery occurred 
12.1 wk after sampling (SD, 2.3; range, 4 d to 17 wk). Eighteen women (6.5%) delivered before 37 wk [in 
Flanders, the premature delivery rate for singleton pregnancies is 6.0% (38)]. The newborn population consisted 
of 141 girls (50.7%) and 137 boys. Mean birth weight was 3390 g (SD, 535; range, 520-4790), length was 50.5 
cm (SD, 2.7; range, 28-56), head circumference was 34.6 cm (SD, 1.4; range, 29.5-38.5), and placental weight was 
573 g (SD, 121; range, 100-1130). Regarding the birth weight percentile distribution, 8.3% were below or at the 
10th percentile (P10), 11.9% were between P11 and P25, 22.3% were between P26 and P50, 27.0% were between P51 
and P75, 15.5% were between P76 and P90, and 15.1% were more than P90. 
There was a wide variation in most plasma parameters, particularly in insulin levels. Because the histogram of 
insulin levels showed an unequal distribution, we used log10-transformed values, which were compatible with a 
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TABLE 1. Data of 289 pregnant women at the glucose challenge test 
 Mean SD Range 
Age (yr) 29.7 4.6 15-44 
Gestational age (wk) 26.8 1.6 24-29 
Body weight (kg) 72.4 12.2 49.1-115
BMI (kg/m2) 26.1 4.3 18.1-41.3
Plasma glucose (mmol/liter) 6.7 1.8 2.7-12.1 
Plasma insulin (pmol/liter) 600 433 116-5112
Plasma PGH (pmol/liter) 492 289 53-2177 
Plasma IGF-I (nmol/liter) 28.8 9.9 4.2-69.3 
Plasma IGFBP-1 (pmol/liter) 1440 624 334-5222
Plasma leptin (pmol/liter) 800 435 91-2750 
 
Correlation and multiple regression analysis of plasma PGH, IGF-I, IGFBP-1, and leptin levels 
In Table 2, we show the correlation coefficients between maternal age, GA, BW, and BMI, and the various 
plasma parameters. On the basis of this analysis, independent variables were introduced for PGH, IGF-I, IGFBP-
1, and leptin in a multiple regression analysis (Table 3); either BW or BMI was introduced, whichever correlated 
better. In the PGH model, only GA and BW were significant determinants of PGH levels. One-way ANOVA 
confirmed that PGH levels were related to GA; PGH levels were higher at 27-29 wk than 24-26 wk (Fig. 1, left 
panel). PGH concentrations gradually declined with increasing BW (Fig. 1, right panel). In the model for IGF-I, 
PGH was the most significant determinant, and then insulin; age (negatively) and BMI were less robust 
determinants. One-way ANOVA showed a trend (P = 0.099) for an effect of GA on IGF-I levels, and subsequent 
post hoc analysis showed that IGF-I levels were higher (P < 0.05) at 29 wk than between 24 and 27 wk (data not 
shown). 
The BMI, as well as insulin and IGF-I levels, but not GA, were determinants of IGFBP-1 levels; none of these 
factors was predominant in the regression model, however. The simple R2 (i.e. the R2 value that would be 
obtained if IGFBP-1 were regressed only against one particular variable) was 9.9, 12.9, and 10.2% for BMI, 
insulin, and IGF-I, respectively. 
The BMI was by far the most powerful determinant of plasma leptin levels, with insulin as a smaller 
determinant. The simple R2 was 41.4 and 12.4% for BMI and insulin, respectively. Leptin levels were 
significantly different in each of the BMI quartiles (ANOVA, P < 0.0001) (data not shown). 
Relation to plasma glucose levels 
Seventy-two women (24.9%) had a plasma glucose level of at least 7.8 mmol/liter. Women with a positive GCT 
tended to have a higher BW (P = 0.06) and BMI (P = 0.05) than women with a normal GCT. Figure 2 shows 
that, in contrast to the difference in insulin levels, there was no difference in PGH, IGFBP-1, or leptin levels 
among women with a normal vs. abnormal GCT. Neither were plasma IGF-I levels different between the two 
groups (P = 0.32). 
TABLE 2. Pearson correlation coefficients between variables at the time of the glucose challenge test 
 Age GA BW/BMI Glucose Log10 insulin PGH IGF-I IGFBP-1 
BW/BMI NS NS       
Glucose 0.19a NS 0.16a/0.17a      
Log10 insulin NS NS 0.27a/0.34a 0.41a     
PGH NS 0.35a -0.29a/-0.26a NS -0.14b    
IGF-I -0.13b 0.19a 0.11c/0.14b NS 0.27a 0.25a   
IGFBP-1 NS -0.10c -0.27a/-0.32a NS -0.36a NS -0.33a  
Leptin NS NS 0.62a/0.64a 0.12b 0.36a -0.22a 0.14b -0.31a
aP < 0.01; bP < 0.05; cP < 0.10. 
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TABLE 3. Multiple regression of PGH, IGF-I, IGFBP-1, and leptin levels at the time of the glucose challenge 
test 
 T-value P R2 (%)
PGH    
GA 6.46 <0.0001 11.8 
BW -5.20 <0.0001 7.6 
Leptin  NS  
Intercept -2.51 0.01  
Total R2 = 0.20 (P < 0.0001)    
IGF-I    
Age -2.15 0.03 1.4 
GA  NS  
BMI 2.36 0.02 1.7 
Insulin 4.11 <0.0001 5.1 
PGH 5.76 <0.0001 10.0 
Leptin  NS  
Intercept  NS  
Total R2 = 0.18 (P < 0.0001)    
IGFBP-1    
GA  NS  
BMI -3.61 <0.001 3.7 
Insulin -3.95 <0.001 4.4 
IGF-I -4.17 <0.0001 5.0 
Leptin  NS  
Intercept 12.92 <0.0001  
Total R2 = 0.22 (P < 0.0001)    
Leptin    
BMI 12.24 <0.0001 31.1 
Glucose  NS  
Insulin 3.13 0.001 2.0 
PGH  NS  
IGF-I  NS  
Intercept -7.55 <0.0001  
Total R2 = 0.43 (P < 0.0001)    
R2 (%), Incremental last R2, i.e. R2 that would be reduced if this variable were removed from the model. 
FIG. 1. Effect of increasing GA (in weeks, left panel) and body weight (in quartiles, right panel) on plasma 
placental GH concentrations. Data are shown as box plots; the number of data in each group is given in the box. 
Statistical procedure is one-way ANOVA, followed by Fisher's LSD multiple comparison test. Groups that are 
significantly different (P < 0.05) from one another are denoted by different letters. 
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FIG. 2. Comparison of insulin, PGH, IGFBP-1, and leptin concentrations between women with a normal GCT 
(white bars) and women with an impaired GCT (glucose level ≥ 7.8 mmol/ liter; hatched bars). Data are means 
± SD; the number of data are given in the bars. Plasma glucose levels were 5.9 ± 1.1 mg/dl in the normal-GCT 
group, and 9.1 ± 1.0 mg/dl in the impaired-GCT group. Statistical procedure is unpaired t tests, taking the 
variance of the data into account. 
 
Parameters at birth 
The birth weight percentile distribution was skewed to the right compared with Flemish reference charts (χ2 test, 
P = 0.003) (38). As expected, birth weight, length, head circumference, and placental weight were highly 
correlated with one another and with GA at birth (P < 0.001). GA at birth was slightly higher in girls than in 
boys (39.1 ± 1.3 vs. 38.7 ± 1.9 wk; P = 0.049); none of the biometric parameters at birth were significantly 
different in girls vs. boys, although the PI tended to be higher in girls (P = 0.07). 
Relation between maternal parameters at the GCT and birth and placental weights 
Maternal BW, height, and BMI were related to birth weight percentile distribution. The effect of BW is shown in 
Fig. 3 (left panel); the relation with height and BMI was equally strong (ANOVA, P < 0.001). In contrast, birth 
weight distribution was not significantly related to maternal PGH (ANOVA, P = 0.30), IGF-I (P = 0.16), 
IGFBP-1 (P = 0.55), or leptin levels (P = 0.32). The analyses remained unchanged when restricted to women 
who were not diagnosed with glucose intolerance, to women who remained normotensive throughout pregnancy, 
or to women of European ancestry (data not shown). Figure 3 (right panel) shows that there was no significant 
difference in PGH, IGF-I, IGFBP-1, and leptin levels between women who subsequently delivered babies no 
more than P50, compared with women who delivered babies more than P50. 
The significant effect of GA at sampling on PGH levels might obscure a relation between PGH and birth weight. 
Hence, we performed two-factor ANOVA, with GA as the first factor and birth weight distribution (≤ P50 vs. > 
P50) as the second; GA was a significant (P < 0.0001) determinant of PGH levels, but not birth weight percentile 
(P > 0.05). 
Placental weight was correlated with maternal BW at sampling (R = 0.28; P < 0.0001), but there was no 
correlation between placental weight and plasma PGH, IGF-I, IGFBP-1, and leptin. 
We found no significant differences in BW/BMI or in any of the plasma parameters between mothers who were 
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FIG. 3. Left, Maternal BW at the time of the GCT according to different birth weight P subgroups. Data are 
shown as box plots, and the number of data in each group is given in the box. Statistical procedure is one-way 
ANOVA, followed by Fisher's LSD multiple comparison test. Values that are significantly different (P < 0.05) 
from the P10 or less, P11-25, P26-50, P51-75, P76-90, and more than P90 groups are denoted by a, b, c, d, e, and f, 
respectively. Right, Comparison between plasma PGH, IGF-I, IGFBP-1, and leptin concentrations at the time of 
the GCT in women who delivered babies with a birth weight that was either no more than P50 (white bars) or 
more than P50 (hatched bars). Statistical procedure is unpaired t tests, taking the variance of the data into 
account. 
 
Relation between maternal parameters at the GCT and the PI at birth 
At birth, 9% of the newborns were thin, 74% normal, and 17% obese. The PI at birth was related to maternal BW 
and BMI (ANOVA, P = 0.02 and P = 0.008, respectively). This effect was even more pronounced in the 
subgroup of women not diagnosed with glucose intolerance (95% of the cohort). Figure 4 (left panel) shows that 
BW was higher in women who later delivered obese babies, compared with thin or normal babies. Plasma 
glucose, insulin, PGH, IGF-I, and IGFBP-1 levels were not significantly different among women who delivered 
thin, normal, or obese babies (data not shown). However, leptin levels were higher in women who delivered 
obese babies compared with normal babies (Fig. 4, right panel). 
Discussion 
In this cohort of 289 mostly Caucasian women, 24.9% had a positive GCT (≥140 mg/dl), which is slightly higher 
than in a large cohort in Toronto, Canada (21%) (39). That the study cohort was at somewhat higher risk for 
GDM can be inferred from the finding that the cohort was older than the general Belgian parturient population. 
Indeed, some physicians followed the recent American Diabetes Association recommendation that Caucasian 
women younger than 25 yr of age without other risk factors need not be screened for GDM (22). We confirmed 
that maternal age was positively correlated with post-GCT glucose levels. In addition, in comparison with the 
Belgian newborn population, the birth weight distribution was slightly skewed to the right. However, in terms of 
parity and the incidence of preterm delivery, hypertension, etc., the cohort is representative of the Belgian 
pregnant population. 
We found that plasma PGH, IGF-I, IGFBP-1, and leptin levels at the GCT were all correlated with BW and 
BMI. Not surprisingly, the correlation was strongest by far for leptin. But we also demonstrated, for the first 
time, a relatively strong negative correlation between BW/BMI and PGH levels. Adiposity has been shown to 
negatively affect GH concentrations; in obese men, the number of GH secretory bursts is lower than in nonobese 
men, and GH clearance is accelerated (40). PGH has 93% DNA sequence identity with GH, but its secretion is 
nonpulsatile and depends primarily on the placental mass (34). It would be interesting to examine in a future 
study whether maternal BW affects PGH half-life. Differences in GH binding in the circulation do not explain 
the altered metabolic clearance rate of GH in obese individuals (40). Also, McIntyre et al. (14) found no 
meaningful differences in GH-binding protein levels among healthy women, diabetic women, and women with 
IUGR fetuses at 28-wk GA, and there was an excellent correlation between total and free PGH levels. 
The concentrations of PGH, and to a lesser extent those of IGF-I, were positively correlated with GA at 
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sampling, confirming the well characterized rise in PGH and IGF-I levels during pregnancy (3, 4). Unlike 
BW/BMI, this effect can be observed within a 6-wk interval in the second half of pregnancy in a relatively large 
cohort of women. We did not confirm recently reported data that PGH levels were different according to the sex 
of the fetus (41). PGH was the major determinant of IGF-I concentrations, confirming the strong correlation 
between both variables in normal and IUGR pregnancies (3,4,10). We have reported that PGH and IGF-I 
concentrations were within the normal range and were highly correlated in a pregnant woman with absent GH 
secretion owing to pit-1-deficiency (35). The discrepant relation between BW and PGH (negative) vs. BW and 
IGF-I (positive) may be explained by the fact that insulin is a second important determinant of IGF-I levels. 
Finally, it is well known that IGF-I levels decline with age in men and nonpregnant women (36); the present 
study extends this data to pregnant women between 15 and 44 yr of age. 
FIG. 4. Maternal BW (left panel) and plasma leptin concentrations (right panel) at the time of the glucose 
challenge test, according to the PI of the newborn at birth: thin (PI < 2.32), normal (PI 2.32-2.84), or obese (PI 
≥ 2.85). Data are shown as box plots, and the number of data are given in the box. Statistical procedure is one-
way ANOVA, followed by Fisher's LSD multiple comparison test. Groups that are significantly different (P < 
0.05) from one another are denoted by different letters. 
 
The IGFBP-1 levels in this study were three to four times higher than those we previously measured in 
nonpregnant women (37). The GCT stimulates insulin secretion, and the down-regulation of IGFBP-1 by insulin 
and IGF-I is well documented (7). However, Baldwin et al. found that IGFBP-1 levels 60 min after a 50-g 
glucose load at 20-24 wk were 95% of fasting levels (15). IGFBP-1 levels exhibit a diurnal variation with a 
nocturnal and early morning rise, but IGFBP-1 varied little between 0900 and 1900 h during the second half of 
pregnancy (42). We found that IGFBP-1 was negatively correlated with BMI and with insulin and IGF-I levels; 
the multiple regression was unable to give predominance to any of these factors. There is some evidence in vitro 
that pituitary GH suppresses the hepatic IGFBP-1 production (43), but we did not find a significant correlation 
between PGH and IGFBP-1 levels. 
The effect of the GCT on leptin levels was probably small; in both healthy and GDM women, no difference was 
found between fasting and 30-min leptin levels during a 75-g glucose load at 28 wk (19). Again, plasma 
concentrations of leptin show a strong diurnal variation, with a nocturnal peak. During the day, a small, gradual 
rise was documented in nonpregnant women (44), which, if confirmed for pregnant women, would be a 
limitation of this study. In addition to its strong correlation with BMI, we found that leptin was also correlated 
with insulin levels. This confirms data in nonpregnant women and in men that insulin is related to leptin 
independently from its effect on adipose tissue (45-47). 
At the outset of the study, we hypothesized that PGH and/or IGFBP-1 might be implicated in the development of 
insulin resistance and glucose intolerance during pregnancy. However, we found no evidence that supports this 
hypothesis; PGH and IGFBP-1 were not correlated with post-GCT glucose levels, and there was no difference in 
PGH and IGFBP-1 levels between women who had either a normal or an abnormal GCT. Hence, the 
diabetogenic effect of pregnancy is unlikely to be the result of PGH secretion or the increment in IGFBP-1 
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secretion. 
We found that PGH, IGF-I, IGFBP-1, or leptin measurements, performed on average 12 wk before delivery, 
were not predictive of birth weight, the PI at birth, or placenta weight. There was only a trend for leptin levels to 
be higher in women who later delivered obese compared with normal babies. In contrast, maternal BW/BMI was 
a powerful determinant of birth weight percentile and the PI, confirming previous findings (21). Our finding 
appears to contradict previous reports of lower PGH and IGF-I, but higher IGFBP-1 and leptin, levels in women 
who delivered small-for-GA or IUGR babies (4, 10-14, 18). However, these studies focused on specific 
populations: pregnant teenagers, part of whom were still growing (18), or pregnancies in which IUGR had 
already been diagnosed by ultrasound, with or without a deficient uteroplacental supply line diagnosed by 
Doppler measurements (4, 10-14). Also, blood sampling was performed at delivery or shortly before delivery in 
some studies (11-13, 41). We conclude from our data that the measurement of PGH, IGF-I, IGFBP-1, or leptin in 
an unselected pregnant population undergoing a GCT is not predictive of birth weight. 
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